Nimelan | 3194-25-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Nimelan
• 英文别名: [(4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-9-(pyridine-3-carbonyloxy)-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] pyridine-3-carboxylate
• CAS: 3194-25-0
• 化学式: C₃₁H₂₇N₃O₅
• 分子量: 521.6
• InChiKey: BFYWWTIGNJJAHF-LTQSXOHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  90.8
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] MACROCYCLIC PEPTIDES AND DERIVATIVES THEREOF WITH OPIOID ACTIVITY<br/>[FR] PEPTIDES MACROCYCLIQUES ET LEURS DÉRIVÉS À ACTIVITÉ OPIOÏDE
  申请人：UNIV FLORIDA

  公开号：WO2018232285A1

  公开（公告）日：2018-12-20

  The invention relates to macrocyclic peptides and pharmaceutical compositions thereof. The invention further relates to pharmaceutical compositions for modulating opioid receptor activity.

  这项发明涉及大环肽及其药物组合物。该发明还涉及用于调节阿片受体活性的药物组合物。
• [EN] NOVEL OPIOID COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS OPIOÏDES ET LEURS UTILISATIONS
  申请人：RHODES TECH

  公开号：WO2019165298A1

  公开（公告）日：2019-08-29

  This invention relates to novel opioid derivatives of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, R4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of, for example, pain.

  这项发明涉及公式I的新型阿片类衍生物：或其药用可接受的盐或溶剂，其中R1、R3、R4和Z如本公开说明中所定义。该发明还涉及利用这类化合物治疗或预防疼痛等疾病的用途。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
  申请人：Babul Najib

  公开号：US20120065221A1

  公开（公告）日：2012-03-15

  The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.

  本发明涉及口服、治疗有效的3-羟基-N-甲基吗啡酮的延迟作用、延长释放药物组成物，包括延迟起效、延长释放剂型及其使用。